< Back to previous page
Researcher
Philip Van Damme
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
- See also: Philip Van Damme (Flanders Institute for Biotechnology)
Affiliations
- Van Den Bosch Lab (Research group)
Member
From1 Jan 2017 → Today - Laboratory for Neurobiology (VIB-KU Leuven) (Lab)
Member
From1 Jan 2012 → Today - Research Group Experimental Neurology (Division)
Member
From1 Oct 2000 → 31 Dec 2011
Projects
1 - 10 of 49
- Towards mechanistic biomarkers for amyotrophic lateral sclerosisFrom1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mapping the microglial heterogeneity in C9orf72-ALS and sporadic ALS using single cell profilingFrom1 Nov 2023 → TodayFunding: BOF - postdoctoral mandates
- A multi-modal and longitudinal approach to study the neurobiological underpinnings of disease onset and progression in genetic ALS variants: from presymptomatic to symptomatic disease stages.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutationsFrom19 Apr 2023 → 31 Dec 2023Funding: Foundations, funds and other with scientific goal
- Measuring brain activation non-invasively in freely moving healthy and neuropsychiatric human populations using functional near-infrared spectroscopy (fNIRS)From1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Investigating the role of cilia dysfunction in Amyotrophic Lateral SclerosisFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis (ALS): cell death pathways and/or aberrant communication between cell body and neuromuscular junctionsFrom1 Oct 2022 → TodayFunding: BOF - projects
- A multi-modal approach to study C9orf72-mediated diseaseFrom16 May 2022 → 15 May 2023Funding: BOF - postdoctoral mandates
- Biomarkers in asymptomatic carriers of ALS-related mutationsFrom1 Apr 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding lysosomal dysfunction in the frontotemporal dementiaamyotrophic lateral sclerosis spectrum of neurodegenerative disorders.From1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
Publications
21 - 30 of 341
- FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and mechanisms(2023)
Authors: Lisanne Terrie, Pegah Masrori, Philip Van Damme, Lieven Thorrez, Ludo Van Den Bosch
- Effect of neurofilament analysis on the diagnostic delay in amyotrophic lateral sclerosis.(2023)
Authors: Pegah Masrori, Philip Van Damme, Koen Poesen
Pages: 70 - 77 - Unravelling the mechanisms of motor neuron degeneration in relation to TDP-43 pathology in amyotrophic lateral sclerosis(2022)
Authors: Evelien Van Schoor, Dietmar Thal, Ludo Van Den Bosch, Philip Van Damme
- Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data(2022)
Authors: Wim Robberecht, Philip Van Damme
- Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial(2022)
Authors: Philip Van Damme, Koen Demaegd
- The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration(2022)
Authors: Wim Robberecht, Philip Van Damme
- Clinical trials in pediatric ALS: a TRICALS feasibility study(2022)
Authors: Philip Van Damme
Pages: 481 - 488 - The International Society for the Study of Vascular Anomalies (ISSVA) ontology(2022)
Authors: Philip Van Damme
- Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol(2022)
Authors: Philip Van Damme
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS(2022)
Authors: Philip Van Damme
Pages: 1099 - 1110